# A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

> **NCT01853852** · PHASE1 · COMPLETED · sponsor: **Amicus Therapeutics** · enrollment: 14 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** GR181413A/AT1001 solution
- **DRUG:** GR181413A/AT1001 capsule
- **OTHER:** Potable water
- **DRUG:** Placebo capsule

## Key facts

- **NCT ID:** NCT01853852
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01853852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01853852, "A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01853852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*